Be part of the knowledge.

ReachMD is even better when
you join the community!
Registration is free and easy.

Register Now

Highlights from the 17th Annual IASLC World Conference on Lung Cancer: International Focus on Emerging Advances in NSCLC Management

Based on CDC data, lung cancer represents 13% of all cancers diagnosed worldwide, and 19% of all cancer deaths. With almost 225,000 cases and more ...

Available credits: 0.25

Time to complete: 15 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Based on CDC data, lung cancer represents 13% of all cancers diagnosed worldwide, and 19% of all cancer deaths. With almost 225,000 cases and more than 158,000 deaths anticipated in 2016 in the United States alone, lung cancer is the leading cause of cancer-associated mortality. Non-small cell lung cancer represents approximately 85% of those cases, which makes the need to better identify and treat this disease a critical need. 

    Join us as Dr. Caudle and Dr. Garon review data on non-small cell lung cancer presented at the 17th annual World Conference on Lung Cancer held in Vienna, Austria.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, The Omnia-Prova Education Collaborative (TOPEC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TOPEC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Edward B. Garon, MD
    Assistant Professor, Medicine and Hematology-Oncology
    Director of Thoracic Oncology Program
    David Geffen School of Medicine at UCLA
    Santa Monica, CA

    Dr. Garon receives research grants from AstraZeneca, Bristol-Myers Squib, Boehringer Ingelheim, Genentech, Eli Lilly, Maruti Pharma, Merck, Novartis, and Pfizer.

    Jennifer Caudle, DO
    Assistant Professor
    Department of Family Medicine at Rowan University-School of Osteopathic Medicine
    Stratford, New Jersey

    Dr. Caudle has nothing to disclose.


    • Sean T. Barrett has nothing to disclose.
    • Barry A. Fiedel, PhD has nothing to disclose.
    • Kia K. Gray, MPH has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Suresh S. Ramalingam, MD receives consulting fees from AbbVie, Amgen, AstraZeneca, BMS, Celgene, Genentech, Lilly, Novartis.
    • Jennifer Spear Smith, PhD has nothing to disclose.
  • Learning Objectives

    At the conclusion of this CME activity, participants managing patients with non-small-cell lung cancer (NSCLC) will be better able to:

    • Discuss the potential of biomarkers to identify patients likely to respond to therapy with an anti-PD-1/PD-L1 agent.
    • Select patients in whom use of agents targeting checkpoint inhibition may be contraindicated.
    • Evaluate the emerging application of combined/sequential use of agents targeting checkpoint inhibition as well as their utilization in patients with NSCLC treated with chemotherapy.
    • Discuss the potential value of agents targeting checkpoint inhibition in small cell lung cancer and mesothelioma.
  • Target Audience

    This activity is designed to meet the educational needs of oncologists.

  • Accreditation and Credit Designation Statements

    The Omnia-Prova Education Collaborative, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The Omnia-Prova Education Collaborative, Inc. designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education designs educational activities based on evidence-based medicine, needs and gaps analyses, learner feedback, and more. Its mission is to serve as an innovative and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.

    Prova Education

  • Commercial Support

    This activity is supported by an independent educational grant from Merck.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of TOPEC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

You must be in to display playlists.

Get a Dose of ReachMD in Your Inbox
and Practice Smarter Medicine

Stay current with the best in medical education.